|
Latest News on Avandia: German Study Adds More Reasons to Avoid it
July 12, 2007--In the latest news on Avandia, a review by German researchers indicates that little evidence supports using Avandia (rosiglitazone) to improve the quality or length of life among adults with diabetes.
The review appears in the latest issue of the Cochrane Collaboration, a publication of the Cochrane Collaboration, an international organization that evaluates medical research.
The authors pooled data from 18 randomized controlled trials including more than 8,000 participants. About half of the patients took Avandia and the other received either an alternative medication or a placebo.
The data suggest that the drug might worsen complications of the disease such as bone fractures and heart disease. The review supports findings from an analysis of studies, published in May, which reported an increased risk of death from cardiovascular causes in patients taking the medication.
If you or a loved one has suffered cardiac complications after ingesting Avandia, you deserve the guidance of an experienced drug attorney. Get a free case review by filling out the form below.
see also:
Study, 7.12.07
Latest News on Avandia: German Study Adds More Reasons to Avoid itLatest Study in the News: Avandia May Worsen Complications of Diabetes
Avandia Panel, 7.25.07
Academic Panel of Scientists to Meet With FDA Regarding Avandia RisksScientific Panel to Advise FDA on Avandia Heart Attack Risk
